Interestingly, among the ERGs recapitulated with model v4, there were well-known NFκB pathway regulators40,41 (e.g., A20) and TFs (e.g., JUNB and KLF10), which are key inflammation and breast cancer regulators33,39,48. This evidence concerns the gene NFKB1 and breast carcinoma.